Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
Patients with ALK + mNSCLC treated with second-generation ALK TKIs as 1L targeted therapies faced a high burden of BM. Incident BM were associated with increased mortality risk to a greater extent than baseline BM. Efforts are needed to provide safe and efficacious approaches to prevention and treatment of BM, including additional monitoring as required, in patients with ALK + mNSCLC.
Authors
- Benjamin Li (ORCID: https://orcid.org/0000-0002-1783-7013)
- Angela Sang
- Lyudmila Bazhenova
- Zachary A. Marcum (ORCID: https://orcid.org/0000-0002-4690-2304)
- Devin Abrahami (ORCID: https://orcid.org/0000-0001-5269-2377)
- N. Rifi (ORCID: https://orcid.org/0009-0004-7627-9519)
- Krishnan Ramaswamy (ORCID: https://orcid.org/0000-0003-0890-0268)
- John M. Kelton (ORCID: https://orcid.org/0000-0002-3308-0276)
- Dipesh Uprety (ORCID: https://orcid.org/0000-0002-4278-9703)
- Matthew D. Davis
- Parag R. Sanghvi
Institutions
- Pfizer (United States) (US)
- UC San Diego Health System (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Medication Management (United States) (US)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108436
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Pfizer